1. Home
  2. ELME vs DVAX Comparison

ELME vs DVAX Comparison

Compare ELME & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELME
  • DVAX
  • Stock Information
  • Founded
  • ELME 1960
  • DVAX 1996
  • Country
  • ELME United States
  • DVAX United States
  • Employees
  • ELME N/A
  • DVAX N/A
  • Industry
  • ELME Real Estate Investment Trusts
  • DVAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ELME Real Estate
  • DVAX Health Care
  • Exchange
  • ELME Nasdaq
  • DVAX Nasdaq
  • Market Cap
  • ELME 1.4B
  • DVAX 1.3B
  • IPO Year
  • ELME N/A
  • DVAX 2004
  • Fundamental
  • Price
  • ELME $16.58
  • DVAX $10.65
  • Analyst Decision
  • ELME Hold
  • DVAX Buy
  • Analyst Count
  • ELME 6
  • DVAX 4
  • Target Price
  • ELME $18.20
  • DVAX $26.50
  • AVG Volume (30 Days)
  • ELME 1.3M
  • DVAX 1.4M
  • Earning Date
  • ELME 08-05-2025
  • DVAX 08-07-2025
  • Dividend Yield
  • ELME 4.33%
  • DVAX N/A
  • EPS Growth
  • ELME N/A
  • DVAX N/A
  • EPS
  • ELME N/A
  • DVAX N/A
  • Revenue
  • ELME $245,911,000.00
  • DVAX $316,268,000.00
  • Revenue This Year
  • ELME $4.84
  • DVAX $21.18
  • Revenue Next Year
  • ELME $0.80
  • DVAX $16.83
  • P/E Ratio
  • ELME N/A
  • DVAX N/A
  • Revenue Growth
  • ELME 4.59
  • DVAX 26.66
  • 52 Week Low
  • ELME $13.95
  • DVAX $9.22
  • 52 Week High
  • ELME $18.49
  • DVAX $14.63
  • Technical
  • Relative Strength Index (RSI)
  • ELME 58.26
  • DVAX 44.22
  • Support Level
  • ELME $16.31
  • DVAX $9.86
  • Resistance Level
  • ELME $16.65
  • DVAX $12.06
  • Average True Range (ATR)
  • ELME 0.33
  • DVAX 0.45
  • MACD
  • ELME 0.08
  • DVAX -0.09
  • Stochastic Oscillator
  • ELME 91.19
  • DVAX 28.41

About ELME Elme Communities

Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: